Less invasive treatments for pure aortic insufficiency: Are we there yet?
TAVR
aortic insufficiency
aortic valve
Journal
Journal of cardiac surgery
ISSN: 1540-8191
Titre abrégé: J Card Surg
Pays: United States
ID NLM: 8908809
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
received:
08
01
2022
accepted:
10
01
2022
pubmed:
22
1
2022
medline:
4
3
2022
entrez:
21
1
2022
Statut:
ppublish
Résumé
The gold standard for the treatment of pure aortic insufficiency (PAI) is surgical valve repair or replacement. With the newest transcatheter heart valve technologies and the accumulating years of experience of heart teams with the current transcatheter aortic valve replacement (TAVR) prostheses, implanters have pushed the envelope with off-label use of those valves designed and approved for aortic stenosis, in patients with PAI especially those at higher risks or for compassionate use. However, new prostheses are currently under investigation in clinical use and evidence is provided on the safety and efficacy of those latter. Will be discussed in this commentary, the actual clinical evidence and the use of transcatheter heart valves, in- and off-label, for the treatment of PAI.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
893-894Informations de copyright
© 2022 Wiley Periodicals LLC.
Références
Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2017;70(2):252-289.
Maurer G. Aortic regurgitation. Heart. 2006;92(7):994-1000.
Praz F, Windecker S, Huber C, Carrel T, Wenaweser P. Expanding indications of transcatheter heart valve interventions. J Am Coll Cardiol Interv. 2015;8(14):1777-1796.
Hira RS, Vemulapalli S, Li Z, et al. Trends and outcomes of off-label use of transcatheter aortic valve replacement: insights from the NCDR STS/ACC TVT registry. JAMA Cardiol. 2017;2(8):846-854.
Alharbi AA, Khan MZ, Osman M, et al. Transcatheter aortic valve replacement vs surgical replacement in patients with pure aortic insufficiency. Mayo Clin Proc. 2020;95(12):2655-2664.
Yoon S-H, Schmidt T, Bleiziffer S, et al. Transcatheter aortic valve replacement in pure native aortic valve regurgitation. J Am Coll Cardiol. 2017;70(22):2752-2763.
Roy DA, Schaefer U, Guetta V, et al. Transcatheter aortic valve implantation for pure severe native aortic valve regurgitation. J Am Coll Cardiol. 2013;61(15):1577-1584.
Sawaya FJ, Deutsch M-A, Seiffert M, et al. Safety and efficacy of transcatheter aortic valve replacement in the treatment of pure aortic regurgitation in native valves and failing surgical bioprostheses: results from an international registry study. J Am Coll Cardiol Interv. 2017;10(10):1048-1056.
Frerker C, Schewel J, Schewel D, et al. Expansion of the indication of transcatheter aortic valve implantation: feasibility and outcome in "off-label" patients compared with “on-label” patients. J Invasive Cardiol. 2015;27(5):229-236.
Koren O, Patel V, Kaewkes D, et al. Transcatheter aortic valve replacement for bicuspid aortic insufficiency after valve-sparing aortic root replacement. JACC Case Rep. 2021;3(17):1798-1802.
Ranard LS, Kaple R, Khalique OK, et al. First transfemoral implantation of a novel transcatheter valve in an LVAD patient with aortic insufficiency. JACC Case Rep. 2021;3(17):1806-1810.
Purita PAM, Tahoces LS, Fraccaro C, et al. Transcatheter treatment of native aortic valve regurgitation: results from an international registry using the transfemoral ACURATE neo valve. Int J Cardiol Heart Vasc. 2020;27:10048.
Seiffert M, Bader R, Kappert U, et al. Initial German experience with transapical implantation of a second-generation transcatheter heart valve for the treatment of aortic regurgitation. J Am Coll Cardiol Interv. 2014;7:1168-1174.
Silaschi M, Conradi L, Wendler O, et al. The JUPITER registry: one-year outcomes of transapical aortic valve implantation using a second generation transcatheter heart valve for aortic regurgitation. Catheter Cardiovasc Interv. 2018;91(7):1345-1351.
Liu L, Yao X, Peng Y, et al. One-year outcome after transcatheter aortic valve replacement for aortic regurgitation: a single-center study. J Card Surg. 2022.
Tung M, Wang X, Li F, et al. A versatile transapical device for aortic valvular disease: one-year outcomes of a multicenter study on the J-Valve system. J Cardiol. 2018;72(5):377-384.